These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 18470950

  • 21. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing.
    Bartlett DW, Davis ME.
    Biotechnol Bioeng; 2007 Jul 01; 97(4):909-21. PubMed ID: 17154307
    [Abstract] [Full Text] [Related]

  • 22. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.
    Alshamsan A, Hamdy S, Samuel J, El-Kadi AO, Lavasanifar A, Uludağ H.
    Biomaterials; 2010 Feb 01; 31(6):1420-8. PubMed ID: 19913908
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. siRNA-mediated antitumorigenesis for drug target validation and therapeutics.
    Lu PY, Xie FY, Woodle MC.
    Curr Opin Mol Ther; 2003 Jun 01; 5(3):225-34. PubMed ID: 12870431
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.
    Wang XL, Xu R, Lu ZR.
    J Control Release; 2009 Mar 19; 134(3):207-13. PubMed ID: 19135104
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes.
    Oliveira S, van Rooy I, Kranenburg O, Storm G, Schiffelers RM.
    Int J Pharm; 2007 Mar 01; 331(2):211-4. PubMed ID: 17187949
    [Abstract] [Full Text] [Related]

  • 31. Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity.
    Zintchenko A, Philipp A, Dehshahri A, Wagner E.
    Bioconjug Chem; 2008 Jul 01; 19(7):1448-55. PubMed ID: 18553894
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Biodegradable polymer-mediated sh/siRNA delivery for cancer studies.
    Jere DJ, Cho CS.
    Methods Mol Biol; 2010 Jul 01; 623():243-69. PubMed ID: 20217556
    [Abstract] [Full Text] [Related]

  • 34. Advances in the development of siRNA-based therapeutics for cancer.
    Shen Y.
    IDrugs; 2008 Aug 01; 11(8):572-8. PubMed ID: 18683092
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Development of a functionalized polymer for stent coating in the arterial delivery of small interfering RNA.
    San Juan A, Bala M, Hlawaty H, Portes P, Vranckx R, Feldman LJ, Letourneur D.
    Biomacromolecules; 2009 Nov 09; 10(11):3074-80. PubMed ID: 19761207
    [Abstract] [Full Text] [Related]

  • 37. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape.
    Endoh T, Ohtsuki T.
    Adv Drug Deliv Rev; 2009 Jul 25; 61(9):704-9. PubMed ID: 19383521
    [Abstract] [Full Text] [Related]

  • 38. Efficient siRNA delivery based on PEGylated and partially quaternized polyamine nanogels: enhanced gene silencing activity by the cooperative effect of tertiary and quaternary amino groups in the core.
    Tamura A, Oishi M, Nagasaki Y.
    J Control Release; 2010 Sep 15; 146(3):378-87. PubMed ID: 20621664
    [Abstract] [Full Text] [Related]

  • 39. Cationic lipids and polymers mediated vectors for delivery of siRNA.
    Zhang S, Zhao B, Jiang H, Wang B, Ma B.
    J Control Release; 2007 Oct 18; 123(1):1-10. PubMed ID: 17716771
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.